Zoono Group (ASX:ZNO) - Managing Director & CEO, Paul Hyslop (Second from left)
Managing Director & CEO, Paul Hyslop (Second from left)
Source: Zoono Group
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Zoono Group (ZNO) has entered a distribution agreement with Al Rabban Capital to distribute its products in the Middle East and North Africa regions
  • Like many other companies across the globe, Al Rabban Capital has shown interest in Zoono’s antimicrobial technology that is more than 99.99 per cent effective
  • Sales of these sanitisation products have raked in millions of dollars so far for the company as a result of the coronavirus
  • Al Rabban Capital has placed an initial order of NZ$2.4 million and Zoono will deliver its product in 1000 litre totes
  • Al Rabban will then repackage them locally
  • The exclusive agreement is for an initial 5 year term and minimum purchase orders will need to increase by 10 per cent annually
  • Zoono Group is up 5.91 per cent and shares are trading for $1.35 each

Zoono Group (ZNO) has entered an exclusive distribution agreement with Al Rabban Capital to distribute Zoono’s products in the Middle East and North Africa regions.

Al Rabban Capital provides professional services with extensive networks, investments and distribution channels in the MENA (Middle East North Africa) Region.

Like many other companies across the globe, Al Rabban Capital has shown interest in Zoono’s sanitisation technology.

Just over one week ago, the company reported earning NZ$11 million in sales over just 11 weeks this year – this reflects weekly sales of about NZ$1 million.

Zoono’s antimicrobial technology odourless, non-leaching, environmentally safe, non-corrosive and, most of all, is deadly for a wide range of bacteria and mould.

In saying that, the products are gentle on humans and animals.

When Zoono’s sanitisers are applied to your skin or a surface, it attracts and destroys bacteria and pathogens.

The company’s Z-71 Microbe Shield and hand sanitiser have recently been tested against the COVID-19 surrogate, Feline Coronavirus, and has shown to be more than 99.99 per cent effective.

These results, coupled with its 30-day extended efficacy on surfaces, have resulted in numerous enquiries from potential customers all over the world.

The agreement with Al Rabban Capital is for an initial five year term, however it can be renewed for a further five years.

Al Rabban Capital’s annual purchase orders will need to be a minimum of NZ$4.8 million in the first 12 months, NZ$8 million in year two and NZ$ 12 million in year three. Following this, orders will need to increase by 10 per cent per annum.

Al Rabban Capital has placed an initial order of NZ$2.4 million and Zoono will deliver its product in 1000 litre totes which Al Rabban will then repackage locally.

Zoono Group is up 5.91 per cent and shares are trading for $1.35 each at 2:53 pm AEDT.

ZNO by the numbers
More From The Market Herald
Paradigm Biopharmaceuticals (ASX:PAR) - CEO, Marco Polizzi

" Paradigm Biopharmaceuticals (ASX:PAR) enters trading halt amid cap raise

Paradigm Biopharmaceuticals (ASX:PAR) has entered into a trading halt ahead of a capital raise.
HITIQ (ASX:HIQ) - CEO, Mike Vegar

" HITIQ (ASX:HIQ) secures third Australian innovation patent

HITIQ (ASX:HIQ) has secured a third Australian innovation patent related to its virtual reality (VR) concussion…

" Medlab Clinical (ASX:MDC) sees depression patent accepted in Europe

Medlab Clinical's (ASX:MDC) patent for depression is formally accepted by the European Patent Office.
The Market Herald Video

" Patrys (ASX:PAB) confirms PAT-DX1 improves efficacy of radiation therapy

Patrys (ASX:PAB) has released pre-clinical data for an animal study of its lead PAT-DX1 product showing…